NDAORALTABLET
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
LEQSELVI (deuruxolitinib phosphate) by PharmaIN is (jak) inhibitor. First approved in 2024.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEQSELVI (deuruxolitinib phosphate) is an oral JAK inhibitor that selectively targets JAK1, JAK2, and TYK2 to modulate cytokine signaling and immune function. The drug was approved by the FDA on July 25, 2024, and represents a new entrant in the JAK inhibitor class. Patient indications and specific therapeutic uses are not yet publicly disclosed in available labeling.
Growth18.3 years to LOE
Early-stage growth product with no established market share yet; commercial team is scaling launch infrastructure and building awareness in target segments.
Mechanism of Action
(JAK) inhibitor. JAKs mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEQSELVI is in early commercial launch phase with minimal linked job postings to date; roles will scale as market traction develops. Career opportunity centers on launch team participation, competitive positioning, and establishing prescriber relationships in what is likely an immunology or hematology indication.
Brand Manager
Worked on LEQSELVI at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.